


- a<sup>3</sup>  
contd
12. (Amended) A solid oral dosage form according to claim 7 comprising 20 to 360 mg of valsartan.

Add the following claims:

a<sup>4</sup>

15. A method of treating obstructive airways diseases, wherein the diseases are selected from the group consisting of chronic obstructive pulmonary disease, adult respiratory distress syndrome, sepsis syndrome, pneumonia, aspiration of gastric content, chest trauma, shock, burns, fat embolia, cardiopulmonary bypass, O<sub>2</sub> toxicity, haemorrhagic pancreatitis, interstitial and bronchoalveolar inflammation comprising administering a therapeutically effective amount of valsartan of formula



to a patient in need thereof.

16. The method of claim 15 wherein chronic obstructive pulmonary disease includes bronchitis, chronic bronchitis, emphysema, asthma, cystic fibrosis, interstitial lung disease, pulmonary vascular disease and increased resistance to airflow during forced expiration.
17. A solid oral dosage form according to claim 8 comprising 20 to 65% of valsartan.
18. A solid oral dosage form according to claim 9 comprising 20 to 65% of valsartan.
19. A solid oral dosage form according to claim 10 comprising 20 to 65% of valsartan.
20. A solid oral dosage form according to claim 8 comprising 20 to 360 mg of valsartan.
21. A solid oral dosage form according to claim 9 comprising 20 to 360 mg of valsartan.